Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy; Pembrolizumab Interventions: Drug: Pembrolizumab; Drug: Cisplatin; Drug: Carboplatin; Drug: Nedaplatin; Drug: Nab paclitaxel; Drug: Docetaxel; Drug: Liposomal paclitaxel; Drug: Fluorouracil Sponsors: Beijing Tongren Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | HNSCC | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Skin Cancer | Squamous Cell Carcinoma | Taxotere